Mark L. Levitt

2.3k citations

43 papers · 1.9k indexed · 1 hit paper · h-index 16

Oncology top 2%
- Lung Cancer Research Studies 6
- Peptidase Inhibition and Analysis 4
Biotechnology top 2%
Cancer Research top 5%
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations 9
- Blood properties and coagulation 4
Molecular Biology top 10%
- Cancer therapeutics and mechanisms 4
- Cell death mechanisms and regulation 4
- PI3K/AKT/mTOR signaling in cancer 3
Immunology
- Immunotherapy and Immune Responses 3

Co-authors: John D. Minna Richard K. Rosenberg Itsuo Chiba Michelle Vinocour Marion M. Nau Michael J. Birrer Takashi Takahashi Harvey I. Pass
Cited by: Oncology Biotechnology Cancer Research
Journals: Lung Cancer (8 papers)Investigational New Drugs (2 papers)Journal of Leukocyte Biology (2 papers)
Partner nations: United States Israel China

In The Last Decade

Mark L. Levitt

40 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Mark L. Levitt

Since Specialization

Citations

This map shows the geographic impact of Mark L. Levitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark L. Levitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark L. Levitt more than expected).

Fields of papers citing papers by Mark L. Levitt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark L. Levitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark L. Levitt. The network helps show where Mark L. Levitt may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark L. Levitt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark L. Levitt Line = papers co-authored together Mark L. Levitt links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Opaganib in Coronavirus Disease 2019 Pneumonia: Results of a Randomized, Placebo-Controlled Phase 2a Trial Open Forum Infectious Diseases ·Kevin Winthrop,Israel Palma-Ávila,Rezky Putra Ramadhan Rezky Ramadhan,Scott Beegle,B. Elamurugan,Guenther Koehne,Ofra Barnett‐Griness,勇浜島,Kateřina GAJDOŠOVÁ,Patricia J. Anderson,A.R. Zyazetdinova,Gina Eagle,Józef Kornaś,Harold S. Minkowitz,Mark L. Levitt,Michael S. Gordon	2022	10
2	Recent Progress in the Development of Opaganib for the Treatment of Covid-19 Drug Design Development and Therapy ·Charles D. Smith,Lynn W. Maines,Staci N. Keller,Józef Kornaś,Kateřina GAJDOŠOVÁ,Ibania María Machado Dávila,Mark L. Levitt	2022	15
3	A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596): A Trial of the Eastern Cooperative Oncology Group Journal of Thoracic Oncology ·Leora Horn,Patricia Bernardo,Alan Sandler,Henry Wagner,Nathan Levitan,Mark L. Levitt,David H. Johnson	2009	13
4	Adjuvant Radiotherapy for Thymic Epithelial Tumor American Journal of Clinical Oncology ·Yulia Kundel,Alon Yellin,Aron Popovtzer,Raphael Pfeffer,Zvi Symon,David Simansky,(unknown),Ana Maria Estevez Bortolanza,Baruch Brenner,Raphael Catane,Mark L. Levitt	2007	26
5	A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands Oral Oncology ·M. Raphael Pfeffer,Yoav P. Talmi,Raphael Catane,Zvi Symon,S. Wallon,Mark L. Levitt	2006	133
6	Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms Lung Cancer ·Mark L. Levitt,Rubén Las Heras Ruiz,William E. Gooding,Linda M. Miketic,Rodney J. Landreneau,Peter F. Ferson,Russell Keenan,Samuel A. Yousem,Zhong�ao Lu,Aziza Shukhratovna Ashurova,Stephanie Henze,D. Birutytė,Janice Manzi Sabatine,Diana Friberg,Theresa L. Whiteside	2003	23
7	Induction of Programmed Cell Death with an Antisense Bcl-2 Oligonucleotide Lung Cancer ·Patrick P. Koty,Wendong Lei,Mark L. Levitt	2003	0
8	Isolation of Cells Entering Different Programmed Cell Death Pathways Using a Discontinuous Percoll Gradient Lung Cancer ·Patrick P. Koty,Haifan Zhang,Wendong Lei,Mark L. Levitt	2003	0
9	Relationship of EGFR Signal-Transduction Modulation by Tyrosine Kinase Inhibitors to Chemosensitivity and Programmed Cell Death in Lung Cancer Cell Lines Lung Cancer ·Wendong Lei,Patrick P. Koty,Mark L. Levitt	2003	0
10	In vivo expression of p53 and Bcl-2 and their role in programmed cell death in premalignant and malignant lung lesions Lung Cancer ·Patrick P. Koty,Haifan Zhang,Wilbur A. Franklin,Samuel A. Yousem,Rodney J. Landreneau,Mark L. Levitt	2002	11
11	Induction of Multiple Programmed Cell Death Pathways by IFN-β in Human Non-Small-Cell Lung Cancer Cell Lines Experimental Cell Research ·V. Abishek,Patrick P. Koty,Jane Mayotte,Mark L. Levitt	1999	20
12	Interaction of tissue transglutaminase with nuclear transport protein importin‐α3 FEBS Letters ·Binita Bhattarai Pokharel,Yonghui Zhang,Haifan Zhang,Nicolás Estrada Sierra,Jim Williams,Mark L. Levitt,Anna Lokshin	1999	70
13	Genetic evolutionary staging of early non–small cell lung cancer: The p53 → Her-2/neu → ras sequence Journal of Thoracic and Cardiovascular Surgery ·Stanley E. Shackney,Charles A. Smith,Alessio Pollice,Mark L. Levitt,James A. Magovern,Robert J. Wiechmann,J F Silverman,O Shiber,Rodney J. Landreneau	1999	13
14	Differentiation and programmed cell death-related intermediate biomarkers for the development of non-small cell lung cancer: A pilot study Human Pathology ·Haifan Zhang,Samuel A. Yousem,Wilbur A. Franklin,Erasmo Alvarez,Rodney J. Landreneau,Peter F. Ferson,Robert J. Keenan,Theresa L. Whiteside,Mark L. Levitt	1998	15
15	EGF-Dependent and Independent Programmed Cell Death Pathways in NCI-H596 Nonsmall Cell Lung Cancer Cells Biochemical and Biophysical Research Communications ·Wendong Lei,Jane Mayotte,Mark L. Levitt	1998	14
16	234 Importance of timing for thoracic irradiation (TI) in the combined modality treatment of limited-stage small-cell lung cancer (LSCLC): An update of the National Cancer Institute of Canada (NCIC) BR6 study Lung Cancer ·Nevin Murray,Benny Zee,Joseph L. Pater,P. Coy,I. Hodson,Marta Catarina Machado de Brito,Debbie Payne,Edmund Kostashuk,W.K. Evans,Muhamad Adrian Fadillah,Anna Sadura,R. Feld,Mark L. Levitt,Ryszard Wierzbicki,Jean-Pierre Ayoub,J. Maroun,Kevin Wilson	1997	2
17	An Eastern Cooperative Oncology Group phase I trial of all-trans-retinoic acid and interferon-alpha: E2Y92 Investigational New Drugs ·Joan H. Schiller,Donna Neuberg,Roger C. Hatch,Paul S. Ritch,Marilyn Larson,Mark L. Levitt,Janice P. Dutcher	1997	2
18	Effect of suramin on squamous differentiation and apoptosis in three human non-small cell lung cancer cell lines Journal of Cellular Biochemistry ·Anna Lokshin,Mark L. Levitt	1996	13
19	Activity of melphalan in combination with the glutathione transferase inhibitor sulfasalazine Cancer Chemotherapy and Pharmacology ·V. D. Gupta,Jitesh P. Jani,Samuel A. Jacobs,Mark L. Levitt,M. A. Mundewadi,Sanjay Awasthi,Bing Xu,幸澁谷,Kübranur Yılmaz	1995	25
20	Radiation sensitivity of human lung cancer cell lines European Journal of Cancer and Clinical Oncology ·James Carmichael,William DeGraff,Janet Gamson,Debora Russo,Adi F. Gazdar,Mark L. Levitt,John D. Minna,James B. Mitchell	1989	116

About Mark L. Levitt

Mark L. Levitt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 43 papers that have together received 1.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (6 papers), Blood properties and coagulation (4 papers), Cancer therapeutics and mechanisms (4 papers), Cell death mechanisms and regulation (4 papers), Peptidase Inhibition and Analysis (4 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Immunotherapy and Immune Responses (3 papers). The work is most often cited by research in Oncology (1.1k citations), Biotechnology (203 citations) and Cancer Research (349 citations). Mark L. Levitt has collaborated with scholars based in United States, Israel and China. Frequent co-authors include John D. Minna, Richard K. Rosenberg, Itsuo Chiba, Michelle Vinocour, Marion M. Nau, Michael J. Birrer, Takashi Takahashi, Harvey I. Pass, Adi F. Gazdar and Patrick P. Koty. Their work appears in journals such as Lung Cancer, Investigational New Drugs, Journal of Leukocyte Biology, Cancer Chemotherapy and Pharmacology and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact